Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in PD-1/PD-L1 Resistant Squamous Lung Cancer (S1400F)
NCT03373760Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2017
- Primary completion
- May 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in squamous cell carcinoma of the lung (SCCL), sponsored by SWOG Cancer Research Network. Started Nov 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT03373760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03373760.